Short answer
Rezolute, Inc. (RZLT) filed an 8-K current report with the SEC on May 4, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Rezolute disclosed oral presentation results from its Phase 3 sunRIZE study on May 1, 2026.
Rezolute, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Rezolute disclosed oral presentation results from its Phase 3 sunRIZE study on May 1, 2026
- Phase 3 data represents a potentially material clinical catalyst for the company’s development pipeline
- Presentation materials contain forward-looking statements subject to clinical, regulatory, and execution risks
- Investors should review Exhibit 99.1 for the study results and supporting data
Item EX-99.1 · Exhibit EX-99.1
- Additional CGM analyses showed >50% reductions in hypoglycemia time and ~50-65% fewer weekly events versus placebo across timepoints
- Normoglycemia exposure increased ~25-50%, while average glucose rose ~10-15% versus placebo
- Phase 3 primary endpoint failed: SMBG-measured weekly hypoglycemia reductions were not statistically significant
- FDA Type B meeting requested broader study data, leaving ersodetug’s congenital HI approval path unresolved
- All 59 completers entered the open-label extension; 57 remain after approximately 6-24 months, with reduced background therapies reported
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Rezolute, Inc. 8-K filings
Get the next RZLT 8-K as it lands
Follow RZLT for push alerts, or ask the research agent what this filing means.